News from ASCO: Alpharadin Significantly Improves Overall Survival in Phase III Trial in Patients
Good news for patients with castration-resistant prostate cancer that has spread to the bone
June 6, 2011 -- PCF's Take: Bayer Healthcare announced promising results for Alpharadin (radium-223 chloride) at the American Society of Clinical Oncology (ASCO) annual meeting on Monday. In the Phase III clinical trial, Alpharadin improved overall survival by about 3 months for patients with castration-resistant prostate cancer and bone metastases. Based on a recommendation by the Independent Data Monitoring Committee (IDMC), the clinical trial will be stopped and patients on the placebo will be given the drug. Due to this success, Bayer is re-evaluating its strategy and timeline for gaining FDA approval.
Alpharadin is an alpha-pharmaceutical and the treatment is the first of its kind. By carrying microscopic amounts of radium, Alpharadin enters a patient’s bone and disperses small amounts of radiation, attacking the prostate cancer. The Prostate Cancer Foundation was the first foundation to fund the proof of concept of alpha-pharmaceuticals at University of Texas MD Anderson Cancer Center through Dr. Christopher J. Logothetis.
If approved by regulatory agencies, Alpharadin will join the growing number of new drugs that have been released in the past 14 months including Provenge, Cabazitaxel and Abiraterone.